Progression of macular atrophy after PDT combined with the COX-2 inhibitor nabumetone in the treatment of neovascular ARMD

Biomedical Papers

Volumn 158, Issue 1, 2014, Pages 138-143

  Sin, Martin ^a   Chrapek, Oldrich ^a   Karhanova, Marta ^a   Pracharova, Zuzana ^a   Langova, Katerina ^b   Rehak, Jiri ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Age related macular degeneration; CD36 metabolic pathway; Choroidal atrophy; Combination therapy; Cyclooxygenase 2; Macula atrophy progression; Nabumetone

Indexed keywords

ALKANONE; CYCLOOXYGENASE 2 INHIBITOR; NABUMETONE; PHOTOSENSITIZING AGENT; PORPHYRIN; VERTEPORFIN;

AGED; ATROPHY; CHOROID; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MACULAR DEGENERATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA LUTEA; VASCULARIZATION; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ATROPHY; BUTANONES; CHOROID; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84897456243     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.066     Document Type: Article

References (26)

1. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. TAP report 1. Arch Ophthalmol 1999;117:1329-45.
2. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.
3. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M, Bartz-Schmidt KU, Grisanti S. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006;142:95-104.
4. Tatar O, Shinoda K, Adam A, Eckert T, Eckardt C, Lucke K, Deuter C, Bartz-Schmidt KU, Grisanti S. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. Br J Ophthalmol 2007;91:166-73.
5. Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina 2009;29:133-48.
6. Rajakariar R, Yaqoob MM, Gilroy DW. COX-2 in inflammation and resolution. Mol Interv 2006;6:199-207.
7. Davies NM, Good RL, Roupe KA, Yáñez JA. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? - Not as easy as 1, 2, 3. J Pharm Pharm Sci 2004;7:217-26.
8. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004;10:3331-48.
9. Maloney SC, Fernandes BF, Castiglione E, Antecka E, Martins C, Marshall JC, Di Cesare S, Logan P, Burnier MN Jr. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patiens. Retina 2009;29:176-80.
10. Hu W, Criswell MH, Ottlecz A, Cornell TL, Danis RP, Lambrou GN, Ciulla TA. Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model. Retina 2005;25:1054-64.
11. Chan CK, Pham LN, Zhou J, Spee C, Ryan SJ, Hinton DR. Differential expression of proand antiangiogenic factors in mouse straindependent hypoxia-induced retinal neovascularization. Lab Invest 2005;85:721-33.
12. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002;62:3956-61.
13. Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 2004;79:275-85.
14. Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003;44:974-9.
15. Takahashi H, Yanagi Y, Tamaki Y, Uchida S, Muranaka K. COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochem Biophys Res Commun 2004;325(2):461-6.
16. Hedner T, Samulesson O, Währborg P, Wadenvik H, Ung KA, Ekbom A. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 2004;64:2315-43.
17. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-278.
18. Dewi NA, Yuzawa M, Tochigi K, Kawamura A, Mori R. Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area. Jpn J Ophthalmol 2008;52(4):277-81.
19. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
20. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-22.
21. Adjunctive diclofenac with verteporfin (ADD-V) study group. Effect of adjunctive diclofenac with verteporfin therapy to treat choroval neovascularisation due to age-related macular degeneration. Phase II study. Retina 2007;27:693-700.
22. Ranchod TM, Guercio JR, Ying GS, Brucker AJ, Stoltz RA. Effect of aspirin therapy on photodynamic therapy with verteporfin for choroidal neovascularization. Retina 2008;28:711-6.
23. Debefve E, Pegaz B, Ballini JP, Konan YN, van den Bergh H. Combination therapy using aspirin-enhanced photodynamic selective drug delivery. Vascul Pharmacol 2007;46:171-80.
24. van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Pharmacol 2002;53:644-647.
25. Houssier M, Raoul W, Lavalette S, Keller N, Guillonneau X, Baragatti B, Jonet L, Jeanny JC, Behar-Cohen F, Coceani F, Scherman D, Lachapelle P, Ong H, Chemtob S, Sennlaub F. CD36 Deficiency Leads to Choroidal Involution via COX2 Down-Regulation in Rodents. PLoS Med 5(2):e39. doi:10.1371/journal.pmed.0050039
26. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.